ペモリン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

ペモリン 価格

MSDS Information

• Pemoline

ペモリン 化学特性,用途語,生産方法

• 効能

  抗うつ薬, 催眠鎮静薬, 中枢神経刺激薬

• 化学的特性

  White Solid

• 使用

  A CNS stimulant. Controlled Substance

• 定義

  ChEBI: A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.

• 世界保健機関（WHO）

  Pemoline was introduced in 1975 for the treatment of attentiondeficit disorder. Because of its central stimulating effects it has also been used in weight control in combination with anorectic agents, laxatives.

• 一般的な説明

  Pemoline, 2-amino-5-phenyl-4(5H)-oxazolone (Cylert), hasa unique structure.
  The compound is described as having an overall effect onthe CNS like that of methylphenidate. Pemoline requires 3to 4 weeks of administration, however, to take effect. A partialexplanation for the delayed effect may be that one of theactions of the agent, as observed in rats, is to increase therate of synthesis of DA.

• 生物活性

  Long-acting central stimulant that induces self-injurious behavior in rats. Acts as an indirect monoamine agonist.

ペモリン 上流と下流の製品情報

ペモリン スペクトルデータ(¹HNMR、¹³CNMR、IR1、Raman)

2152-34-3, ペモリン キーワード